Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

ClinicalTrials.gov ID: NCT00005051

Public ClinicalTrials.gov record NCT00005051. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of First-Line Therapy of Ovarian Cancer With Sequential Regimens: Cisplatin-Prolonged Oral Topotecan (C-PORT) Followed by Paclitaxel/Carboplatin (PC)

Study identification

NCT ID: NCT00005051
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: NYU Langone Health; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Ovarian Cancer

Interventions

carboplatin Drug
cisplatin Drug
paclitaxel Drug
topotecan hydrochloride Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 1999
Primary completion: Feb 28, 2003
Completion: Not listed
Last update posted: Nov 8, 2012

Started 1999

United States locations

U.S. sites: 10
U.S. states: 2
U.S. cities: 5

Facility	City	State	ZIP	Site status
New York Hospital Medical Center of Queens	Fresh Meadows	New York	11365	—
Saint Vincent Catholic Medical Center of New York	New York	New York	10011	—
NYU School of Medicine's Kaplan Comprehensive Cancer Center	New York	New York	10016	—
St. Luke's-Roosevelt Hospital Center - Roosevelt Division	New York	New York	10019	—
New York Weill Cornell Cancer Center at Cornell University	New York	New York	10021	—
Mount Sinai Medical Center, NY	New York	New York	10029	—
Herbert Irving Comprehensive Cancer Center at Columbia University	New York	New York	10032	—
Albert Einstein Clinical Cancer Center	The Bronx	New York	10461	—
New York Medical College	Valhalla	New York	10595	—
University of Wisconsin Comprehensive Cancer Center	Madison	Wisconsin	53792-3236	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00005051, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 8, 2012 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00005051 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →